T4455

Sigma-Aldrich

TEV Protease

NACRES:
NA.54
En este momento no podemos mostrarle ni los precios ni la disponibilidad

Quality Level

recombinant

expressed in E. coli

description

Contains both a histidine tag and a GST tag

form

aqueous glycerol solution

specific activity

≥3,000 units/mg protein

mol wt

27 kDa

shipped in

wet ice

storage temp.

−20°C

General description

TEV protease has (NIa) protease catalytic domain which corresponds to a molecular weight of 27 kDa. It is unique with high specificity and is active at low temperature.
The tobacco etch virus (TEV) protease is a useful tool for the removal of fusion tags from recombinant proteins.

Application

TEV Protease has been used in the removal of histidine tag from recombinant mitogen activated protein kinase 14 (MAPK14), Connexin43 (Cx43) c-terminal fragment and δ1-pyrroline-5-carboxylate reductase from Oryza sativa. It has also been used in the elution of purified proteasomes from human leukemia cell lines K562.

Biochem/physiol Actions

Immobilized TEV protease on streptavidin-agarose is an efficient tool for fusion protein cleavage. TEV protease has also been used in a study to investigate proteolytic processing of nlrp1b for inflammasome activity.
The tobacco etch virus (TEV) protease undergoes autolysis, but mutants of TEV protease are resistant to autolysis. Bacterial expression of recombinant TEV protease leads to poor yields and less solubility. Use of green fluorescent protein fusion TEV protease overcomes these setbacks and finds application in structural genomics research.
TEV protease has a strict 7 amino acid cleavage recognition sequence of Glu-Asn-Leu-Tyr-Phe-Gln↓Gly/Ser.

Features and Benefits

Optimally engineered and purified for enhanced stability and high specific activity over a broad temperature range.

Physical properties

TEV protease is an engineered catalytic domain of the Tobacco Etch virus NIa protease. TEV protease is a highly specific cystein protease belonging to the C4 peptidase family.
A modified 52 kDa TEV protease construct containing both GST and His tags for easy removal using glutathione or His-Select® affinity media.

Unit Definition

One unit of TEV protease cleaves >85% of 3 μg of control substrate in one hour at pH 8.0 at 30 °C.

Physical form

Supplied as a >=2 mg/ml in 25 mM Tris-HCl, pH 8.0, 50 mM NaCl, 1 mM TCEP, and 50% glycerol

Preparation Note

Cleavage Protocol
Prepare fresh dialysis buffer. Dialysis buffer should be optimized for target protein solubility and contain no protease inhibitors. The dialysis buffer should also be compatible with downstream purification processes, e.g. minimal amount of EDTA or DTT if a HIS Select® column will be used to remove the cleaved His-tag.
Example of suitable dialysis buffer; 25 mM Tris-HCl, pH 8.0, 150 - 500 mM NaCl, 14 mM β-mercaptoethanol
This TEV protease has the same activity in 150 mM NaCl or 500 mM NaCl and 400 mM imidazole.
Dilute the target protein sample to 1-2 mg/ml with dialysis buffer. This is optional in case the target protein aggregates in dialysis buffer. Save a small aliquot as a control for PAGE analysis. EDTA may be added to 0.5 mM final concentration if the target protein will be eluted from the HIS Select column and EDTA is compatible with the target protein.
Add TEV protease at a protease to target protein ratio of 1:100 (w/w) or 10,000 unit (1 mg) TEV protease to 100 mg of target protein. There is no need to calculate the molar ratio. TEV protease can be added directly to the target protein. There is no need to change buffer or dilute TEV protease. The optimal ratio should be determined empirically. A Protease-to-target protein ratio (w/w) of 1:50 to 1:200 should provide an affective range for most target proteins.
Dialyze against the dialysis buffer at 4 °C ~ 16 hrs. Dialysis is intended to remove imidazole or glutathione if HIS Select® or glutathione affinity columns are used to remove the cleaved tag or TEV protease after cleavage.
Typically, 1 mg of TEV protease will cleave >90% of 100mg of a control protein at 4 °C in 16 hours.

Legal Information

HIS-Select is a registered trademark of Sigma-Aldrich Co. LLC
HiScreen is a trademark of Cytiva

RIDADR

NONH for all modes of transport

WGK Germany

WGK 2

Flash Point F

Not applicable

Flash Point C

Not applicable

Connexin43 forms supramolecular complexes through non-overlapping binding sites for drebrin, tubulin, and ZO-1
Ambrosi C, et al.
Testing, 11(6), e0157073-e0157073 (2016)
Coronin 2A (CRN5) expression is associated with colorectal adenoma-adenocarcinoma sequence and oncogenic signalling
Rastetter RH, et al.
BMC Cancer, 15(1), 638-638 (2015)
Egor E Diakonov et al.
Biochemical and biophysical research communications, 508(2), 368-373 (2018-12-07)
The ubiquitin proteasome system is involved in the regulation of most basic intracellular processes, and deregulation of this system can results in certain kinds of human diseases. Proteolytic core this system, the 20S proteasome, has been found in physiological fluids...
Efficient site-specific processing of fusion proteins by tobacco vein mottling virus protease in vivo and in vitro
Nallamsetty S, et al.
Protein Expression and Purification, 38(1), 108-115 (2004)
A novel method for high-level production of TEV protease by superfolder GFP tag
Wu X, et al.
BioMed Research International, 2009 (2010)
Artículos
Read our article about how the Nanodisc system allows for structural studies of membrane proteins.
Más información
This page shows how to perform a purification of His-tagged membrane proteins.
Más información

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico

Redes sociales

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

Merck

Investigación. Desarrollo. Producción.

Somos un proveedor líder para la industria de Ciencias de la Vida con soluciones y servicios para investigación, desarrollo y producción biotecnológicos, y para desarrollo y producción de tratamientos farmacéuticos

© 2021 Merck KGaA, Darmstadt, Alemania y/o sus filiales. Todos los derechos reservados.

Queda estrictamente prohibida la reproducción sin permiso de cualquiera de los materiales de la página web.